The Anti-Infectives Market Outlook to 2013

Content

• The Anti-infectives Market Outlook to 2013 Executive Summary
• Disease overview and epidemiology
• Global market analysis
• Pipeline analysis
• Competitive landscape
• Chapter 1 Scope and methodology 18 Scope
  • Key drug-classes covered in this report
  • Methodology
• Chapter 2 Disease overview and epidemiology
  • Summary
  • Introduction
  • Bacterial infections
  • Overview
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
  • Pharmacological treatment
  • Penicillins
  • Cephalosporins
  • Quinolones
  • Macrolides
  • Vaccines
  • Estimated incidence of bacterial infections
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
  • Forecast epidemiology
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
  • Viral infections
  • AIDS/HIV
  • Pharmacological treatment
  • Estimated incidence of HIV
  • Hepatitis
  • Pharmacological treatment for hepatitis
  • Estimated incidence of Hepatitis
  • Forecast epidemiology
  • Influenza
  • Pharmacological treatment for influenza
  • Estimated incidence of Influenza
  • Herpes
  • Pharmacological treatment for herpes
  • Estimated incidence of herpes
  • Forecast epidemiology
  • Other viral infections
  • Human papillomavirus
  • Rotavirus
  • Fungal infections
  • Pharmacological treatment for fungal infections
  • Estimated incidence of fungal infections
  • Forecast epidemiology
• Chapter 3 Global market analysis
  • Summary
  • Introduction
  • Market analysis by country
  • Licensing trends
  • Market analysis by drug classes
  • Leading brands dynamics
  • Key events in the anti-infectives market
  • Modest growth from Quinolones
  • Drug resistant infections confer long term growth opportunity
  • Novel HIV/AIDS drugs present substantial market opportunity
  • Hepatitis C therapies fuel strong growth through 2013
  • Novel vaccines drive future sales growth
  • Global concerns on potential human avian flu epidemic
  • Anti-bacterials
  • Market analysis by drug class
  • Leading brands of anti-bacterial treatments
  • Cephalosporins
  • Key brand analysis
  • Penicillins
  • Key brand analysis
  • Fluoroquinolones
  • Key brand analysis
  • Macrolides
  • Key brand analysis
  • Carbapenems
  • Key brand analysis
  • Tetracyclines
  • Key brand analysis
  • Other antibiotics
  • Key brand analysis
  • Anti-bacterials sales forecast (20082013)
  • Anti-virals
  • Breakdown of the global anti-virals market
  • Leading brands of anti-virals treatment
  • Key brand analysis
  • Anti-virals sales forecasts (2008 2013)
  • Vaccines
  • Breakdown of the global vaccines market
  • Leading brands of vaccines
  • Key brand analysis
  • Vaccines sales forecasts 20082013
  • Anti-fungals
  • Breakdown of the global anti-fungals market
  • Leading brands of anti-fungals treatment
  • Key brand analysis
  • Anti-fungals sales forecasts 2008-2013
  • Total anti-infective market sales forecasts to 2013
• Chapter 4 Pipeline analysis
  • Summary
  • Introduction
  • Key trends in R&D
  • Key trends in the anti-bacterial market
  • Key trends in the anti-viral market
  • Key trends in the vaccines market
  • Key trends in the anti-fungal market
  • Therapeutic area pipeline
  • Leading drugs in development
  • Profiles of key pipeline products
  • Recently marketed drugs
  • Doribax
  • Isentress
  • Prezista
  • Selzentry
  • Eraxis
  • Gardasil
  • Drugs in registration
  • Ceftobiprole
  • Cervarix
  • Drugs in phase III clinical studies
  • Albuferon
  • Tygacil
  • Numax
  • Telaprevir
  • Vicriviroc
  • Menveo
  • Prevnar 13vPnC
  • Pipeline forecast
  • Factors affecting forecasts
  • Anti-bacterials
  • Anti-virals
  • Anti-fungals
  • Vaccines
• Chapter 5 Competitive landscape
  • Summary
  • Introduction
  • Sales performance among the leading players
  • Detailed analysis of leading anti-infective players
  • GlaxoSmithKline
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Merck
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Pfizer
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Novartis
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Gilead Sciences
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Abbott
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Wyeth
  • Overview
  • Sales Focus By Drug class
  • Marketed Product Portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sanofi-Aventis
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • Strategic and growth analysis
  • Bristol-Myers Squibb
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic growth analysis
  • Johnson & Johnson
  • Overview
  • Sales focus by drug class
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic growth analysis
  • IMS data
  • J1 Systemic antibiotics
  • J2 Systemic agents for fungal infections
  • J5 Antivirals for systemic use
  • J7 Vaccines
  • Index
• List of Figures
  • Figure 3.1: Global anti-infectives market share by geography (%), global, 2007
  • Figure 3.2: Sales revenuesof anti-infectives by licensing status ($m), global, 20062007
  • Figure 4.3: Key trends in the anti-infectives R&D pipelines, 2007-2013
  • Figure 4.4: Anti-infectives pipeline by indication and stage of development, March 2008
  • Figure 4.5: Leading drugs in development, March 2008
  • Figure 4.6: Anti-bacterial pipeline forecast, 20072013
  • Figure 4.7: Anti-viral pipeline forecast, 20072013
  • Figure 4.8: Anti-fungal pipeline forecast, 20072013
  • Figure 4.9: Vaccines pipeline forecast, 20072013
  • Figure 5.10: Market share of key players by sales revenues, 2007
  • Figure 5.11: Forecast market share of leading anti-infectives players by sales revenues, 2013
  • Figure 5.12: Market share and ranking of leading players in the global anti-infectives market, 2007 - 2013
  • Figure 5.13: GSKs anti-infectives product portfolio by drug class, 2007
  • Figure 5.14: Mercks anti-infectives product portfolio by drug class, 2007
  • Figure 5.15: Pfizers anti-infectives product portfolio by drug class, 2007
  • Figure 5.16: Novartis anti-infectives product portfolio by drug class, 2007
  • Figure 5.17: Gilead Sciences anti-infectives product portfolio by drug class, 2007
  • Figure 5.18: Abbotts anti-infectives product portfolio by drug class, 2007
  • Figure 5.19: Wyeths anti-infectives product portfolio by drug class, 2007
  • Figure 5.20: Sanofi-Aventis anti-infectives product portfolio by drug class, 2007
  • Figure 5.21: Bristol Myers Squibbs anti-infectives product portfolio by drug class, 2007
  • Figure 5.22: J&Js anti-infectives product portfolio by drug class, 2007
  • Table 2.1: Estimated incidence of infective diseases, EU5, US and Japan, 2005
  • Table 2.2: Estimated incidence of community acquired pneumonia infections EU5, US and Japan, 2007
  • Table 2.3: Estimated incidence of upper RTIs caused by streptococcus infection, EU5, US and Japan, 2007
  • Table 2.4: Estimated incidence of community acquired urinary tract infections, EU5, US and Japan, 2007
  • Table 2.5: Estimated incidence of bacterial skin and skin structure infections, EU5, US and Japan, 2007
  • Table 2.6: Forecast epidemiology of CAP, EU5, US and Japan, 20072013
  • Table 2.7: Forecast epidemiology of uRTIs caused by streptococcus infection, Eu5, US and Japan, 20072013
  • Table 2.8: Forecast epidemiology of urinary tract infections, EU5, US and Japan, 20072013
  • Table 2.9: Forecast epidemiology of skin and skin structure infections, EU5, US and Japan, 20072013
  • Table 2.10: HIV/AIDS incidence and prevalence ($m), 2005
  • Table 2.11: Estimated incidence of community acquired HBV and HCV infection (000s), EU5, US and Japan, 2007
  • Table 2.12: Forecast epidemiology of HBV, EU5, US and Japan, 200713
  • Table 2.13: Forecast epidemiology of HCV, EU5, US and Japan, 200713
  • Table 2.14: Estimated seroprevalence of HSV - 1 and HSV - 2 infections (000s), Eu5, US and japan, 2007
  • Table 2.15: Forecast seroprevalence of HSV 1, EU5, US and Japan, 200713
  • Table 2.16: Forecast seroprevalence of HSV 2 across the seven major markets, 20072013
  • Table 2.17: Estimated incidence of systemic fungal infections (000s) in EU5, US and Japan, 2007
  • Table 2.18: Forecast epidemiology of systemic fungal infections, EU5, US and Japan, 20072013
  • Table 3.19: Breakdown of the global anti-infectives market by drug class ($m), 20062007
  • Table 3.20: Leading brands in the global anti-infectives market ($m), 20062007
  • Table 3.21: Breakdown of the global anti-bacterial market by drug class ($m), 20062007
  • Table 3.22: Leading anti-bacterials in the global anti-infectives market ($m), 20062007
  • Table 3.23: Leading cephalosporins in the global anti-infectives market ($m), 20062007
  • Table 3.24: Leading penicillins in the global anti-infectives market ($m), 20062007
  • Table 3.25: Leading fluoroquinolones in the global anti-infectives market ($m), 20062007
  • Table 3.26: Leading macrolides in the global anti-infectives market ($m), 20062007
  • Table 3.27: Leading carbapenems in the global anti-infectives market ($m), 20062007
  • Table 3.28: Leading tetracyclines in the global anti-infectives market ($m), 20062007
  • Table 3.29: Leading other anti-bacterials in the global anti-infectives market ($m), 20062007
  • Table 3.30: Anti-bacterials sales forecast ($m), global, 20082013
  • Table 3.31: Anti-bacterials sales forecast ($m), global, 20082013 (continued)
  • Table 3.32: Anti-bacterials sales forecast ($m), global, 20082013
  • Table 3.33: Breakdown of the global anti-virals market by drug class ($m), 20062007
  • Table 3.34: Leading antivirals in the global anti-infectives market ($m), 20062007
  • Table 3.35: Anti-virals sales forecast ($m), global, 2008-2013
  • Table 3.36: Breakdown of the global vaccines market by class ($m), 20062007
  • Table 3.37: Leading vaccines in the global anti-infectives market ($m), 20062007
  • Table 3.38: Global vaccines sales forecast, 20082013 ($m)
  • Table 3.39: Global anti-fungal market, ($m), 20062007
  • Table 3.40: Leading anti-fungal brands in the global anti-infectives market ($m), 20062007
  • Table 3.41: Global anti-fungals sales forecast ($m), 20082013
  • Table 3.42: Global anti-infectives sales forecast ($m), 20082013
  • Table 4.43: Key drug profile, Doripenem
  • Table 4.44: An overview on Isentress
  • Table 4.45: An overview on Prezista
  • Table 4.46: An overview on Selzentry
  • Table 4.47: An overview on Eraxis
  • Table 4.48: An overview on Gardasil
  • Table 4.49: FDA approvals and NDA filings of Gardasil
  • Table 4.50: An overview on Ceftobiprole
  • Table 4.51: An overview on Cervarix
  • Table 4.52: An overview on Albuferon
  • Table 4.53: An overview on Tygacil
  • Table 4.54: An overview on Motavizumab
  • Table 4.55: An overview on Telaprevir
  • Table 4.56: An overview on Vicriviroc
  • Table 4.57: An overview on Menveo
  • Table 4.58: An overview on Prevna13vPnC
  • Table 5.59: Sales performance of the leading players in the global anti-infectives market ($m), 20062007
  • Table 5.60: GSKs leading anti-infectives product sales ($m), 20062007
  • Table 5.61: GSKs anti-infectives product pipeline, 20062007
  • Table 5.62: Mercks leading anti-infectives product sales ($m), 20062007
  • Table 5.63: Mercks anti-infectives product pipeline, 20062007
  • Table 5.64: Pfizers anti-infectives product portfolio, 20062007 ($m)
  • Table 5.65: Pfizers anti-infectives product pipeline, 20062007
  • Table 5.66: Novartis anti-infectives product portfolio, 20062007 ($m)
  • Table 5.67: Novartis anti-infectives product pipeline, 20062007
  • Table 5.68: Gilead Sciences leading anti-infectives product sales, 20062007 ($m)
  • Table 5.69: Gilead Sciences anti-infectives product pipeline, 20062007
  • Table 5.70: Abbotts leading anti-infectives product sales, 20062007 ($m)
  • Table 5.71: Abbotts anti-infectives product pipeline, 20062007
  • Table 5.72: Wyeths leading anti-infectives product sales, 20062007
  • Table 5.73: Wyeths anti-infectives product pipeline, 20062007
  • Table 5.74: Sanofi-Aventis leading anti-infectives product sales, 20062007 ($m)
  • Table 5.75: Sanofi-Aventis anti-infectives product pipeline, 20062007
  • Table 5.76: Bristol Myers Squibbs leading anti-infectives product sales, 20062007 ($m)
  • Table 5.77: Bristol Myers Squibbs anti-infectives product pipeline, 20062007
  • Table 5.78: J&Js leading anti-infectives product sales, 20062007 ($m)
  • Table 5.79: J&Js anti-infectives product pipeline, 20062007